Login to Your Account

Ampio 'PIVOTs,' adds 'SPRING' to its 'STEP' after FDA grants an SPA for Ampion

By Marie Powers
News Editor

Tuesday, September 22, 2015

Ampio Pharmaceuticals Inc. saw its prospects rise, along with its stock price, after the FDA granted an SPA for the newly launched phase III PIVOT (AP-003-B) trial of co-lead candidate Ampion (aspartyl-alanyl diketopiperazine) to treat pain and inflammation due to osteoarthritis of the knee.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription